Market accessOfficial

Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/46

🇬🇧 MHRA · Thu 05 Nov 2026

Sandoz Limited has notified the MHRA of errors in the dosing table of the SmPC for Co-amoxiclav 250/62.5 mg/5 mL Powder for Oral Suspension, issued as a Class 4 (precautionary) defect notification (EL(26)A/46). Because the dosing table guides prescribing and dispensing, the SmPC needs correcting and healthcare professionals should be aware of the error.

Official source: MHRA ↗

Summary written by VigiEye from the official notice. AI-assisted; check the source before acting.

More Market access All →